Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1461-1480 of 2,120 trials

Atrial Fibrillation: IV Flecainide with Ranolazine

We are comparing the effectiveness of a combination of IV flecainide and oral ranolazine against IV flecainide alone for patients with recent onset atrial fibrillation. This study aims to find out which treatment better restores normal heart rhythm.

Atrial Fibrillation (AF)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiology

Leukemia: Venetoclax with Stem Cell Transplant

We are evaluating the safety and effectiveness of Venetoclax combined with standard treatment for patients with high-risk MDS, CMML, or sAML undergoing stem cell transplantation. This study aims to improve outcomes and reduce complications during treatment.

Leukemia>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Ulcerative Colitis in Kids: Risankizumab Study

We are evaluating how well Risankizumab works and its safety for children aged 2 to under 18 with moderately to severely active ulcerative colitis. This study will help us understand how the drug is processed in their bodies.

Ulcerative Colitis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyPediatrics

Ovarian Cancer: HIPEC Treatment Study

We are studying the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) combined with standard care for ovarian cancer patients. This trial aims to see if HIPEC improves survival and quality of life compared to standard treatments alone.

Ovarian and Fallopian Tube CancerConfirmation phase (III)No PlaceboStandard MedicinesOncology

Antibiotic Treatment for Critically Ill Patients

We are studying whether a short course of high-dose antibiotics is as effective as standard treatment for critically ill patients with pneumonia, intra-abdominal infections, or bloodstream infections. This research may help reduce antibiotic use while maintaining patient safety.

Pneumonia and Bacterial Infections>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Juvenile Idiopathic Arthritis: Early Drug Withdrawal Study

We are exploring whether stopping medication early is safe and effective for children with juvenile idiopathic arthritis in remission. This study also aims to identify new biomarkers that may help predict flare-ups after treatment withdrawal.

Juvenile Idiopathic Arthritis3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPediatricsRheumatology

Inflammatory Bowel Disease: Vedolizumab Dose Reduction Study

We are studying whether patients with inflammatory bowel disease can safely lower their dose of vedolizumab. This trial will help us understand the effects on health, costs, and quality of life.

Inflammatory Bowel Disease1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Lupus Nephritis: MSV-ALLO® Treatment Study

We are testing a new cell therapy for lupus nephritis to see if it helps patients achieve remission. The study compares this treatment to a placebo to evaluate its safety and effectiveness.

Lupus Nephritis3-6 monthsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesNephrologyRheumatology

Psoriasis: [18F]Fluoride PET-CT Imaging Study

We are investigating if [18F]Fluoride PET-CT scans can detect early bone changes in psoriasis patients at risk for psoriatic arthritis. This study aims to see if this imaging method is effective for early detection.

Psoriasis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyRheumatology

Lichen Simplex Chronicus: Dupilumab Injections

We are studying whether dupilumab injections can help reduce itching in adults with Lichen Simplex Chronicus who haven't found relief from other treatments. The trial will also look at how this treatment affects sleep and overall quality of life.

Neurodermatitis6-12 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementAllergologyDermatology

Chronic Spontaneous Urticaria: BP11 vs. Xolair

We are comparing a new treatment, BP11, to Xolair for patients with chronic spontaneous urticaria who haven't responded to antihistamines. The goal is to see if BP11 is as effective and safe as Xolair.

Chronic Spontaneous Urticaria6-12 monthsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Avacopan for Children with Active ANCA-associated Vasculitis

We are studying how well Avacopan works when combined with other treatments in children aged 6 to under 18 with active ANCA-associated vasculitis. The trial will also look at safety and how children respond to the medication.

ANCA-associated Vasculitis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Osteosarcoma: Mifamurtide with Chemotherapy

We are studying whether adding mifamurtide to standard chemotherapy helps improve outcomes for patients with high-risk osteosarcoma. This trial is for individuals aged 2 to 50 who are newly diagnosed with this aggressive cancer.

High-Risk Osteosarcoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Gastroenteropancreatic Neuroendocrine Tumors: New Liver Treatment

We are studying a new way to deliver radiolabeled treatments directly to the liver for patients with GEP-NET and dominant liver metastases. This trial aims to see if this method improves treatment effectiveness and safety.

Gastroenteropancreatic Neuroendocrine Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal MedicineOncology

Relapsed or Refractory Tumors: AcSé-ESMART Trial

We are studying new treatment options for children and adolescents with hard-to-treat tumors. The goal is to see if these treatments are safe and effective based on the specific characteristics of their tumors.

Pediatric Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Kidney Transplant: Optimal Dose of Grafalon®

We are studying the best dose of Grafalon® for kidney transplant patients with low immunological risk. This trial aims to prevent complications and evaluate the medication's safety and effects on kidney function and infections.

Kidney TransplantKidney Insufficiency>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNephrology

Post-Surgery Pain Management: Ropivacaine Concentration Study

We are investigating whether different concentrations of ropivacaine can help reduce pain after volar plate surgery. This study aims to see if higher doses lead to less rebound pain and better overall pain control.

Radius Fracture>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteOrthopedics and TraumatologyOtolaryngologyPsychiatry

Thyroid Eye Disease: TOUR006 Treatment Study

We are investigating whether the new treatment TOUR006 can reduce eye bulging in adults with thyroid eye disease. Participants will receive either the treatment or a placebo to compare effects.

Thyroid Eye Disease1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementEndocrinologyOphthalmology

Kidney Health After Liver Transplant: Human Albumin Study

We are investigating whether higher doses of human albumin can help reduce kidney problems after liver transplantation. This study looks at various recovery aspects, including hospital stay and potential complications.

Liver Transplantation≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesHepatologyNephrology

Lung Cancer: Pembrolizumab and Lenvatinib Combination Therapy

We are studying a new combination treatment for patients with operable Non-Small-Cell Lung Cancer to see if it improves response rates before surgery. We also aim to identify markers that may predict how well patients respond to this therapy.

Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPulmonology